BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016;61:540-60. [PMID: 27486148 DOI: 10.1177/0706743716659417] [Cited by in Crossref: 357] [Cited by in F6Publishing: 317] [Article Influence: 59.5] [Reference Citation Analysis]
Number Citing Articles
1 Hejzlar M, Novak T, Bares M. Neurostimulation Methods in the Treatment of Depression: A Comparison of rTMS, tDCS, and Venlafaxine Using a Pooled Analysis of Two Studies. Neuropsychiatr Dis Treat 2021;17:1713-22. [PMID: 34093015 DOI: 10.2147/NDT.S303226] [Reference Citation Analysis]
2 Turna J, Simpson W, Patterson B, Lucas P, Van Ameringen M. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. Journal of Psychiatric Research 2019;111:134-9. [DOI: 10.1016/j.jpsychires.2019.01.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
3 Morthland M, Shah A, Meadows JT, Scogin F. Development of an audio and computer cognitive behavioral therapy for depression in older adults. Aging Ment Health 2020;24:1207-15. [PMID: 31116017 DOI: 10.1080/13607863.2019.1609901] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Aswar M, Bhalekar M, Trimukhe A, Aswar U. Self-microemulsifying drug delivery system (SMEDDS) of curcumin attenuates depression in olfactory bulbectomized rats. Heliyon 2020;6:e04482. [PMID: 32817886 DOI: 10.1016/j.heliyon.2020.e04482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Meng Y, Yuen J. Onset of Transient Sadness Following the Concomitant Use of a Triptan and Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors Therapy: A Case Report. J Pharm Pract 2021;:8971900211064444. [PMID: 34962845 DOI: 10.1177/08971900211064444] [Reference Citation Analysis]
6 Suh JS, Minuzzi L, Raamana PR, Davis A, Hall GB, Harris J, Hassel S, Zamyadi M, Arnott SR, Alders GL, Sassi RB, Milev R, Lam RW, MacQueen GM, Strother SC, Kennedy SH, Frey BN. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. Neuroimage Clin 2020;25:102178. [PMID: 32036277 DOI: 10.1016/j.nicl.2020.102178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kowalczyk M, Kowalczyk E, Kwiatkowski P, Łopusiewicz Ł, Sienkiewicz M, Talarowska M. Ketamine-New Possibilities in the Treatment of Depression: A Narrative Review. Life (Basel) 2021;11:1186. [PMID: 34833062 DOI: 10.3390/life11111186] [Reference Citation Analysis]
8 Lamont R, Rosic T, Sanger N, Samaan Z. Psychosis and Comorbid Opioid Use Disorder: Characteristics and Outcomes in Opioid Substitution Therapy. Schizophr Bull Open 2020;1:sgaa007. [PMID: 32803158 DOI: 10.1093/schizbullopen/sgaa007] [Reference Citation Analysis]
9 Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clin Pharmacol Ther 2021;109:536-46. [PMID: 32860422 DOI: 10.1002/cpt.2024] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S. Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iran J Psychiatry 2021;16:52-9. [PMID: 34054983 DOI: 10.18502/ijps.v16i1.5379] [Reference Citation Analysis]
11 Allen TA, Lam RW, Milev R, Rizvi SJ, Frey BN, Macqueen GM, Müller DJ, Uher R, Kennedy SH, Quilty LC. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychol Med 2019;49:1629-38. [DOI: 10.1017/s0033291718002441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
12 Parikh RB, Gallo JJ, Wong YN, Robinson KW, Cashy JP, Narayan V, Jayadevappa R, Chhatre S. Long-term depression incidence and associated mortality among African American and White prostate cancer survivors. Cancer 2021;127:3476-85. [PMID: 34061986 DOI: 10.1002/cncr.33656] [Reference Citation Analysis]
13 Galán-arroyo C, Pereira-payo D, Hernández-mocholí MÁ, Merellano-navarro E, Pérez-gómez J, Rojo-ramos J, Adsuar JC. Depression and Exercise in Older Adults: Exercise Looks after You Program, User Profile. Healthcare 2022;10:181. [DOI: 10.3390/healthcare10020181] [Reference Citation Analysis]
14 Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M. Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat 2018;14:103-15. [PMID: 29343962 DOI: 10.2147/NDT.S146840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
15 Lin YY, Chang CC, Huang CC, Tzeng NS, Kao YC, Chang HA. Efficacy and neurophysiological predictors of treatment response of adjunct bifrontal transcranial direct current stimulation (tDCS) in treating unipolar and bipolar depression. J Affect Disord 2021;280:295-304. [PMID: 33221715 DOI: 10.1016/j.jad.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kato M, Takekita Y, Koshikawa Y, Sakai S, Bandou H, Nishida K, Sunada N, Onohara A, Hatashita Y, Serretti A, Kinoshita T. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research 2017;89:97-104. [DOI: 10.1016/j.jpsychires.2017.02.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Elbay RY, Görmez A, Kılıç A, Avcı SH. Separation anxiety disorder among outpatients with major depressive disorder: Prevalence and clinical correlates. Compr Psychiatry 2021;105:152219. [PMID: 33378709 DOI: 10.1016/j.comppsych.2020.152219] [Reference Citation Analysis]
18 Bennabi D, Yrondi A, Charpeaud T, Genty JB, Destouches S, Lancrenon S, Allaili N, Bellivier F, Bougerol T, Camus V, Doumy O, Dorey JM, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Aouizerate B, Haffen E, Llorca PM, Courtet P. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental). BMC Psychiatry 2019;19:50. [PMID: 30700272 DOI: 10.1186/s12888-019-2025-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
19 Pompili M, Vazquez GH, Forte A, Morrissette DA, Stahl SM. Pharmacologic Treatment of Mixed States. Psychiatr Clin North Am 2020;43:167-86. [PMID: 32008683 DOI: 10.1016/j.psc.2019.10.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Munkholm K, Winkelbeiner S, Homan P. Individual response to antidepressants for depression in adults-a meta-analysis and simulation study. PLoS One 2020;15:e0237950. [PMID: 32853222 DOI: 10.1371/journal.pone.0237950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
21 Tonon AC, Pilz LK, Markus RP, Hidalgo MP, Elisabetsky E. Melatonin and Depression: A Translational Perspective From Animal Models to Clinical Studies. Front Psychiatry 2021;12:638981. [PMID: 33897495 DOI: 10.3389/fpsyt.2021.638981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Nikkheslat N. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Brain Behav Immun Health 2021;18:100383. [PMID: 34849492 DOI: 10.1016/j.bbih.2021.100383] [Reference Citation Analysis]
23 Thom RP, Palumbo ML, Thompson C, McDougle CJ, Ravichandran CT. Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study. Brain Sci 2021;11:1216. [PMID: 34573236 DOI: 10.3390/brainsci11091216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Lauzier S, Kadachi H, Moisan J, Vanasse A, Lesage A, Fleury MJ, Grégoire JP. Neighbourhood Material and Social Deprivation and Exposure to Antidepressant Drug Treatment: A Cohort Study Using Administrative Data. Can J Psychiatry 2018;63:701-11. [PMID: 29514506 DOI: 10.1177/0706743718760290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 2018;4:CD011006. [PMID: 29683474 DOI: 10.1002/14651858.CD011006.pub3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
26 Vigod SN, Hussain-shamsy N, Stewart DE, Grigoriadis S, Metcalfe K, Oberlander TF, Schram C, Taylor VH, Dennis C. A patient decision aid for antidepressant use in pregnancy: Pilot randomized controlled trial. Journal of Affective Disorders 2019;251:91-9. [DOI: 10.1016/j.jad.2019.01.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Howren A, Aviña-Zubieta JA, Da Costa D, Puyat JH, Xie H, De Vera MA. Impact of arthritis on the perceived need and use of mental healthcare among Canadians with mental disorders: nationally representative cross-sectional study. BMJ Open 2020;10:e041371. [PMID: 33303458 DOI: 10.1136/bmjopen-2020-041371] [Reference Citation Analysis]
29 Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, Worrell C, Enache D, McLaughlin A, Kose M, Sforzini L, Bogdanova A, Cleare A, Young AH, Pariante CM, Mondelli V. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.Neuropsychopharmacology. 2021;46:939-948. [PMID: 33504955 DOI: 10.1038/s41386-020-00948-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
30 Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure 2020;83:104-23. [PMID: 33120323 DOI: 10.1016/j.seizure.2020.09.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
31 Fornaro M, Fusco A, Anastasia A, Cattaneo CI, De Berardis D. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy 2019;20:1925-33. [DOI: 10.1080/14656566.2019.1654457] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Pahlevan T, Ung C, Segal Z. Cost-Utility Analysis of Mindfulness-Based Cognitive Therapy Versus Antidepressant Pharmacotherapy for Prevention of Depressive Relapse in a Canadian Context: Analyse coût-utilité de la thérapie cognitive basée sur la pleine conscience contre la pharmacothérapie antidépressive pour prévenir la rechute de la dépression en contexte canadien. Can J Psychiatry 2020;65:568-76. [PMID: 32031000 DOI: 10.1177/0706743720904613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Han C, Wang G, Chan S, Kato T, Ng CH, Tan W, Zhang L, Feng Y, Liu CY. Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatr Dis Treat 2020;16:2929-41. [PMID: 33311981 DOI: 10.2147/NDT.S264799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Brinsley J, Schuch F, Lederman O, Girard D, Smout M, Immink MA, Stubbs B, Firth J, Davison K, Rosenbaum S. Effects of yoga on depressive symptoms in people with mental disorders: a systematic review and meta-analysis. Br J Sports Med 2021;55:992-1000. [PMID: 32423912 DOI: 10.1136/bjsports-2019-101242] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
35 Wang HR, Bahk WM, Seo JS, Woo YS, Park YM, Jeong JH, Kim W, Shim SH, Lee JG, Jon DI, Min KJ. Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines. Clin Psychopharmacol Neurosci 2017;15:199-209. [PMID: 28783928 DOI: 10.9758/cpn.2017.15.3.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
36 Dell'Osso B, Cremaschi L, Grancini B, De Cagna F, Benatti B, Camuri G, Arici C, Dobrea C, Oldani L, Palazzo MC, Vismara M, Altamura AC. Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. Int J Clin Pract 2017;71. [PMID: 28090727 DOI: 10.1111/ijcp.12926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Santina T, Lauzier S, Gagnon H, Villeneuve D, Moisan J, Grégoire JP, Guillaumie L. The Development of a Community Pharmacy-Based Intervention to Optimize Patients' Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process. Pharmacy (Basel) 2018;6:E39. [PMID: 30720782 DOI: 10.3390/pharmacy6020039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ratzlaff M, Harrington M. A dramatic case of a woman discovered after 7 months of untreated catatonia. Ir J Psychol Med 2018;35:69-73. [PMID: 30115204 DOI: 10.1017/ipm.2016.46] [Reference Citation Analysis]
39 Thom R, Silbersweig DA, Boland RJ. Major Depressive Disorder in Medical Illness: A Review of Assessment, Prevalence, and Treatment Options. Psychosom Med 2019;81:246-55. [DOI: 10.1097/psy.0000000000000678] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 6.7] [Reference Citation Analysis]
40 Tisseverasinghe A, Peschken C, Hitchon C. Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0797-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
41 Kim HK, Zai G, Hennings JM, Müller DJ, Kloiber S. Changes in RNA expression levels during antidepressant treatment: a systematic review. J Neural Transm (Vienna) 2021;128:1461-77. [PMID: 34415438 DOI: 10.1007/s00702-021-02394-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Caldiroli A, Capuzzi E, Riva I, Russo S, Clerici M, Roustayan C, Abbass A, Buoli M. Efficacy of intensive short-term dynamic psychotherapy in mood disorders: A critical review. Journal of Affective Disorders 2020;273:375-9. [DOI: 10.1016/j.jad.2020.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Donneyong M, Reynolds C, Mischoulon D, Chang G, Luttmann-Gibson H, Bubes V, Guilds M, Manson J, Okereke O. Protocol for studying racial/ethnic disparities in depression care using joint information from participant surveys and administrative claims databases: an observational cohort study. BMJ Open 2020;10:e033173. [PMID: 31915172 DOI: 10.1136/bmjopen-2019-033173] [Reference Citation Analysis]
44 Solmi M, Miola A, Croatto G, Pigato G, Favaro A, Fornaro M, Berk M, Smith L, Quevedo J, Maes M, Correll CU, Carvalho AF. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry 2021;43:189-202. [PMID: 32491040 DOI: 10.1590/1516-4446-2020-0935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Cheung CP, Thiyagarajah MT, Abraha HY, Liu CS, Lanctôt KL, Kiss AJ, Saleem M, Juda A, Levitt AJ, Schaffer A, Cheung AH, Sinyor M. The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. J Affect Disord 2021;280:140-7. [PMID: 33212405 DOI: 10.1016/j.jad.2020.11.004] [Reference Citation Analysis]
46 Rathod P, Ould Brahim L, Belzile E, Lambert S. An evaluation of the suitability, readability, and quality of online resources for the self-management of depression. Patient Education and Counseling 2019;102:952-60. [DOI: 10.1016/j.pec.2018.12.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
47 Sayegh L, Touré EH, Farquhar E, Beaulieu S, Renaud S, Rej S, Perreault M. Group Cognitive Behavioral Analysis System of Psychotherapy (CBASP): A Pilot Study for Bipolar Depression. Front Psychiatry 2020;11:565681. [PMID: 33173513 DOI: 10.3389/fpsyt.2020.565681] [Reference Citation Analysis]
48 Miron JP, Voetterl H, Fox L, Hyde M, Mansouri F, Dees S, Zhou R, Sheen J, Desbeaumes Jodoin V, Mir-Moghtadaei A, Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F, Downar J. Optimized repetitive transcranial magnetic stimulation techniques for the treatment of major depression: A proof of concept study. Psychiatry Res 2021;298:113790. [PMID: 33581379 DOI: 10.1016/j.psychres.2021.113790] [Reference Citation Analysis]
49 Jankauskas V, Necyk C, Chue J, Chue P. A review of ketamine's role in ECT and non-ECT settings. Neuropsychiatr Dis Treat 2018;14:1437-50. [PMID: 29922060 DOI: 10.2147/NDT.S157233] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
50 Hu YT, Hu XW, Han JF, Zhang JF, Wang YY, Wolff A, Tremblay S, Tan ZL, Northoff G. Childhood trauma mediates repetitive transcranial magnetic stimulation efficacy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2021. [PMID: 34117915 DOI: 10.1007/s00406-021-01279-3] [Reference Citation Analysis]
51 Kamijima K, Yasuda M, Yamamura K, Fukuta Y. Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Current Medical Research and Opinion 2018;34:2105-12. [DOI: 10.1080/03007995.2018.1519317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Thomson M, Sharma V. Between a rock-a-bye and a hard place: mood disorders during the peripartum period. CNS Spectr. 2017;22:49-64. [PMID: 29350128 DOI: 10.1017/s1092852917000852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
53 Kim JM, Kim HY, Lee HJ, Kim JW, Kang HJ, Kim SW, Shin IS, Chun BJ, Stewart R. Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy. Front Psychiatry 2021;12:747228. [PMID: 34925091 DOI: 10.3389/fpsyt.2021.747228] [Reference Citation Analysis]
54 Brouillette J, Nattel S. A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. Canadian Journal of Cardiology 2017;33:1577-86. [DOI: 10.1016/j.cjca.2017.09.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
55 Haller H, Anheyer D, Cramer H, Dobos G. Complementary therapies for clinical depression: an overview of systematic reviews.BMJ Open. 2019;9:e028527. [PMID: 31383703 DOI: 10.1136/bmjopen-2018-028527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
56 Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, Zhang L, Feng Y, Ng CH. Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatr Dis Treat 2020;16:2943-59. [PMID: 33299316 DOI: 10.2147/NDT.S264813] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 McIntyre RS, Prieto R, Schepman P, Yeh YC, Boucher M, Shelbaya A, Chambers R, Gao X, Pappadopulos E. Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. Curr Med Res Opin 2019;35:2169-77. [PMID: 31370711 DOI: 10.1080/03007995.2019.1652053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Xu T, Xue Y, Lu J, Jin C. Synthesis and biological evaluation of 1-(4-(piperazin-1-yl)phenyl)pyridin-2(1H)-one derivatives as potential SSRIs. Eur J Med Chem 2021;223:113644. [PMID: 34182358 DOI: 10.1016/j.ejmech.2021.113644] [Reference Citation Analysis]
59 Chamberlain SR, Baldwin DS. Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. CNS Drugs 2021;35:703-16. [PMID: 34240393 DOI: 10.1007/s40263-021-00832-x] [Reference Citation Analysis]
60 Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry 2018;31:32-9. [PMID: 29076894 DOI: 10.1097/YCO.0000000000000377] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
61 Thériault FL, Gardner W, Momoli F, Garber BG, Kingsbury M, Clayborne Z, Cousineau-Short DY, Sampasa-Kanyinga H, Landry H, Colman I. Mental Health Service Use in Depressed Military Personnel: A Systematic Review. Mil Med 2020;185:e1255-62. [PMID: 32073617 DOI: 10.1093/milmed/usaa015] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Ou MJ, Huang CC, Wang YC, Chen YL, Ho CH, Wu MP, Huang YT, Wu CY, Chen PJ. Depression is a major risk factor for the development of dementia in people with lower urinary tract symptoms: A nationwide population-based study. PLoS One 2019;14:e0217984. [PMID: 31173611 DOI: 10.1371/journal.pone.0217984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
63 Su JA, Chang CC, Wang HM, Chen KJ, Yang YH, Lin CY. Antidepressant treatment and mortality risk in patients with dementia and depression: a nationwide population cohort study in Taiwan. Ther Adv Chronic Dis 2019;10:2040622319853719. [PMID: 31210918 DOI: 10.1177/2040622319853719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
64 O'Donovan C, Alda M. Depression Preceding Diagnosis of Bipolar Disorder. Front Psychiatry 2020;11:500. [PMID: 32595530 DOI: 10.3389/fpsyt.2020.00500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Higgins GA, Carroll NK, Brown M, MacMillan C, Silenieks LB, Thevarkunnel S, Izhakova J, Magomedova L, DeLannoy I, Sellers EM. Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. Front Pharmacol 2021;12:640241. [PMID: 33716753 DOI: 10.3389/fphar.2021.640241] [Reference Citation Analysis]
66 Li J, Li X, Jiang J, Xu X, Wu J, Xu Y, Lin X, Hall J, Xu H, Xu J, Xu X. The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and Stress in Patients With COVID-19: A Randomized Controlled Trial. Front Psychiatry 2020;11:580827. [PMID: 33192723 DOI: 10.3389/fpsyt.2020.580827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
67 Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol 2021;35:890-900. [PMID: 34238049 DOI: 10.1177/02698811211013579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kim HY, Lee HJ, Jhon M, Kim JW, Kang HJ, Lee JY, Kim SW, Shin IS, Kim JM. Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders. Clin Psychopharmacol Neurosci 2021;19:490-7. [PMID: 34294617 DOI: 10.9758/cpn.2021.19.3.490] [Reference Citation Analysis]
69 Bråten LS, Haslemo T, Jukic MM, Ivanov M, Ingelman-Sundberg M, Molden E, Kringen MK. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram. Clin Pharmacol Ther 2021;110:786-93. [PMID: 33759177 DOI: 10.1002/cpt.2233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
70 Boyce P, Hopwood M, Morris G, Hamilton A, Bassett D, Baune BT, Mulder R, Porter R, Parker G, Singh AB, Outhred T, Das P, Malhi GS. Switching antidepressants in the treatment of major depression: When, how and what to switch to? Journal of Affective Disorders 2020;261:160-3. [DOI: 10.1016/j.jad.2019.09.082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
71 Perna G, Daccò S, Alciati A, Cuniberti F, De Berardis D, Caldirola D. Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2021;107:110208. [PMID: 33338557 DOI: 10.1016/j.pnpbp.2020.110208] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Cassano P, Petrie SR, Mischoulon D, Cusin C, Katnani H, Yeung A, De Taboada L, Archibald A, Bui E, Baer L, Chang T, Chen J, Pedrelli P, Fisher L, Farabaugh A, Hamblin MR, Alpert JE, Fava M, Iosifescu DV. Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomed Laser Surg 2018;36:634-46. [PMID: 30346890 DOI: 10.1089/pho.2018.4490] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
73 Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Brown K, Lewis D, Gutin A, Jablonski MR, Greden JF. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res 2021;296:113649. [PMID: 33360967 DOI: 10.1016/j.psychres.2020.113649] [Reference Citation Analysis]
74 Yang L, Shergis JL, Di YM, Zhang AL, Lu C, Guo X, Fang Z, Xue CC, Li Y. Managing Depression with Bupleurum chinense Herbal Formula: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Journal of Alternative and Complementary Medicine 2020;26:8-24. [DOI: 10.1089/acm.2019.0105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
75 Puzhko S, Schuster T, Barnett TA, Renoux C, Munro K, Barber D, Bartlett G. Difference in patterns of prescribing antidepressants known for their weight-modulating and cardiovascular side effects for patients with obesity compared to patients with normal weight. J Affect Disord 2021;295:1310-8. [PMID: 34706445 DOI: 10.1016/j.jad.2021.08.018] [Reference Citation Analysis]
76 Mosca D, Zhang M, Prieto R, Boucher M. Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline. J Clin Psychopharmacol 2017;37:182-92. [DOI: 10.1097/jcp.0000000000000674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
77 Borrione L, Suen PJC, Razza LB, Santos LAD, Sudbrack-oliveira P, Brunoni AR. The Flow brain stimulation headset for the treatment of depression: overview of its safety, efficacy and portable design. Expert Review of Medical Devices 2020;17:867-78. [DOI: 10.1080/17434440.2020.1813565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 2021. [PMID: 34257409 DOI: 10.1038/s41380-021-01200-3] [Reference Citation Analysis]
79 Caldieraro MA, Cassano P. Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms. Journal of Affective Disorders 2019;243:262-73. [DOI: 10.1016/j.jad.2018.09.048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
80 Seo JS, Bahk WM, Woo YS, Park YM, Kim W, Jeong JH, Shim SH, Lee JG, Jang SH, Yang CM, Wang SM, Jung MH, Sung HM, Choo IH, Yoon BH, Lee SY, Jon DI, Min KJ. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin Psychopharmacol Neurosci 2021;19:751-72. [PMID: 34690130 DOI: 10.9758/cpn.2021.19.4.751] [Reference Citation Analysis]
81 Lim B, Sproule BA, Zahra Z, Sunderji N, Kennedy SH, Rizvi SJ. Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. Int Clin Psychopharmacol 2020;35:243-53. [PMID: 32459725 DOI: 10.1097/YIC.0000000000000316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
82 Taylor RW, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B, Zahn R, Young AH, Cleare AJ. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. Int J Neuropsychopharmacol 2020;23:587-625. [PMID: 32402075 DOI: 10.1093/ijnp/pyaa033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
83 Park LT, Zarate CA Jr. Depression in the Primary Care Setting. N Engl J Med 2019;380:559-68. [PMID: 30726688 DOI: 10.1056/NEJMcp1712493] [Cited by in Crossref: 49] [Cited by in F6Publishing: 22] [Article Influence: 16.3] [Reference Citation Analysis]
84 Lee KH, Bahk WM, Lee SJ, Pae CU. Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice. Clin Psychopharmacol Neurosci 2020;18:621-6. [PMID: 33124595 DOI: 10.9758/cpn.2020.18.4.621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Middleton JC, Kalogeropoulos C, Middleton JA, Drapeau M. Assessing the methodological quality of the Canadian Psychiatric Association's anxiety and depression clinical practice guidelines. J Eval Clin Pract 2019;25:613-21. [DOI: 10.1111/jep.13026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Liu X, Momen NC, Molenaar N, Rommel AS, Bergink V, Munk-Olsen T. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? J Affect Disord 2021;290:254-60. [PMID: 34010750 DOI: 10.1016/j.jad.2021.04.045] [Reference Citation Analysis]
87 Dobson KG, Vigod SN, Mustard C, Smith PM. Major Depressive Episodes and Employment Earnings Trajectories over the Following Decade among Working-aged Canadian Men and Women. J Affect Disord 2021;285:37-46. [PMID: 33626409 DOI: 10.1016/j.jad.2021.02.019] [Reference Citation Analysis]
88 Oswald F, Campbell J, Williamson C, Richards J, Kelly P. A Scoping Review of the Relationship between Running and Mental Health. Int J Environ Res Public Health 2020;17:E8059. [PMID: 33139666 DOI: 10.3390/ijerph17218059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Thomas RK, Baker G, Lind J, Dursun S. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol 2018;32:1110-7. [DOI: 10.1177/0269881118793104] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
90 Mcallister-williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi G, Soares J, Vieta E, Young A, Papadopoulos A, Rush A. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders 2020;267:264-82. [DOI: 10.1016/j.jad.2020.02.023] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
91 Kennedy SH, Ceniti AK. Unpacking Major Depressive Disorder: From Classification to Treatment Selection. Can J Psychiatry 2018;63:308-13. [PMID: 29278937 DOI: 10.1177/0706743717748883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
92 Koprdova R, Csatlosova K, Durisova B, Bogi E, Majekova M, Dremencov E, Mach M. Electrophysiology and Behavioral Assessment of the New Molecule SMe1EC2M3 as a Representative of the Future Class of Triple Reuptake Inhibitors. Molecules 2019;24:E4218. [PMID: 31757051 DOI: 10.3390/molecules24234218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
93 Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med 2020;25:130. [PMID: 31554608 DOI: 10.1136/bmjebm-2019-111238] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
94 Perna G, Alciati A, Daccò S, Grassi M, Caldirola D. Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. Psychiatry Investig 2020;17:193-206. [PMID: 32160691 DOI: 10.30773/pi.2019.0289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
95 Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J, You R, You E, Tanguay-sela M, Snook E, Miresco M, Berlim MT. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. Journal of Affective Disorders 2019;243:503-15. [DOI: 10.1016/j.jad.2018.09.067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
96 Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS, Blier P. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2018;21:128-44. [PMID: 29024974 DOI: 10.1093/ijnp/pyx081] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
97 Zanardi R, Prestifilippo D, Fabbri C, Colombo C, Maron E, Serretti A. Precision psychiatry in clinical practice. Int J Psychiatry Clin Pract 2021;25:19-27. [PMID: 32852246 DOI: 10.1080/13651501.2020.1809680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Bangalore S, Shah R, Gao X, Pappadopulos E, Deshpande CG, Shelbaya A, Prieto R, Stephens J, Chambers R, Schepman P, McIntyre RS. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis. J Med Econ 2020;23:262-70. [PMID: 31665949 DOI: 10.1080/13696998.2019.1686311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Simoons M, Seldenrijk A, Mulder H, Birkenhäger T, Groothedde-Kuyvenhoven M, Kok R, Kramers C, Verbeeck W, Westra M, van Roon E, Bakker R, Ruhé H. Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug Saf 2018;41:655-64. [PMID: 29484613 DOI: 10.1007/s40264-018-0649-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
100 Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders 2019;250:114-22. [DOI: 10.1016/j.jad.2019.03.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
101 Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P. Multi‐trajectories of antidepressant and antipsychotic use: a 11‐year naturalistic study in a community‐based sample. Acta Psychiatr Scand 2019;139:536-47. [DOI: 10.1111/acps.13020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
102 Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA, Kieling C. The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: A systematic review and meta-analysis. Eur Neuropsychopharmacol 2020;33:139-45. [PMID: 32046933 DOI: 10.1016/j.euroneuro.2020.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Lipsitz O, McIntyre RS, Rodrigues NB, Kaster TS, Cha DS, Brietzke E, Gill H, Nasri F, Lin K, Subramaniapillai M, Kratiuk K, Teopiz K, Lui LMW, Lee Y, Ho R, Shekotikhina M, Mansur RB, Rosenblat JD. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Prog Neuropsychopharmacol Biol Psychiatry 2021;105:110126. [PMID: 33031861 DOI: 10.1016/j.pnpbp.2020.110126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
104 Yuan H, Zhu X, Tang W, Cai Y, Shi S, Luo Q. Connectivity between the anterior insula and dorsolateral prefrontal cortex links early symptom improvement to treatment response. J Affect Disord 2020;260:490-7. [PMID: 31539685 DOI: 10.1016/j.jad.2019.09.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
105 Cantù F, Ciappolino V, Enrico P, Moltrasio C, Delvecchio G, Brambilla P. Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression. J Affect Disord 2021;280:45-53. [PMID: 33202337 DOI: 10.1016/j.jad.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Pinto JV, Saraf G, Frysch C, Vigo D, Keramatian K, Chakrabarty T, Lam RW, Kauer-Sant'Anna M, Yatham LN. Cannabidiol as a Treatment for Mood Disorders: A Systematic Review. Can J Psychiatry 2020;65:213-27. [PMID: 31830820 DOI: 10.1177/0706743719895195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
107 Sinyor M, Cheung CP, Abraha HY, Lanctôt KL, Saleem M, Liu CS, Li A, Juda A, Levitt AJ, Cheung AH, Schaffer A. Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. J Affect Disord 2020;267:185-90. [PMID: 32217218 DOI: 10.1016/j.jad.2020.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
108 Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI, Robertson L, Christiaens T. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021;4:CD013495. [PMID: 33886130 DOI: 10.1002/14651858.CD013495.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
109 Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology 2020;13:655-70. [DOI: 10.1080/17512433.2020.1772054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Rush AJ, South CC, Jha MK, Grannemann BD, Trivedi MH. Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. J Affect Disord 2019;242:87-95. [PMID: 30173063 DOI: 10.1016/j.jad.2018.08.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
111 Shamabadi A, Akhondzadeh S. Efficacy and tolerability of Lavandula angustifolia in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. J Complement Integr Med 2021. [PMID: 34420270 DOI: 10.1515/jcim-2020-0498] [Reference Citation Analysis]
112 Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, Suppes T, Lopez Jaramillo C, Trivedi MH, Fava M, Rush AJ, Mcintyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. The World Journal of Biological Psychiatry 2018;19:330-48. [DOI: 10.1080/15622975.2017.1379609] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
113 Maj M, Stein DJ, Parker G, Zimmerman M, Fava GA, De Hert M, Demyttenaere K, McIntyre RS, Widiger T, Wittchen HU. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269-93. [PMID: 32931110 DOI: 10.1002/wps.20771] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 13.5] [Reference Citation Analysis]
114 Razza LB, Afonso dos Santos L, Borrione L, Bellini H, Branco LC, Cretaz E, Duarte D, Ferrão Y, Galhardoni R, Quevedo J, Simis M, Fregni F, Correll CU, Padberg F, Trevizol A, Daskalakis ZJ, Carvalho AF, Solmi M, Brunoni AR. Appraising the effectiveness of electrical and magnetic brain stimulation techniques in acute major depressive episodes: an umbrella review of meta-analyses of randomized controlled trials. Braz J Psychiatry. [DOI: 10.1590/1516-4446-2020-1169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Aouizerate B, El-Hage W. [Only good therapeutic strategies! Response to the letter about the special issue: "All the truth about benzodiapzépines"]. Presse Med 2019;48:217-8. [PMID: 30853283 DOI: 10.1016/j.lpm.2019.02.002] [Reference Citation Analysis]
116 Fiorillo A, Carpiniello B, De Giorgi S, La Pia S, Maina G, Sampogna G, Spina E, Tortorella A, Vita A. Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Front Psychiatry 2018;9:493. [PMID: 30364225 DOI: 10.3389/fpsyt.2018.00493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
117 Fabbri C, Serretti A. How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. Clin Psychopharmacol Neurosci 2020;18:484-92. [PMID: 33124583 DOI: 10.9758/cpn.2020.18.4.484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
118 Jalenques I, Rachez C, Jalenques UT, Nechifor SA, Morel L, Blanchard F, Pereira B, Lauron S, Rondepierre F; French DAS/PDAS group. Cross-cultural evaluation of the French version of the Delusion Assessment Scale (DAS) and Psychotic Depression Assessment Scale (PDAS). PLoS One 2021;16:e0250492. [PMID: 33901242 DOI: 10.1371/journal.pone.0250492] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Kim JM, Stewart R, Kang HJ, Kim JW, Lee HJ, Jhon M, Lee JY, Kim SW, Shin IS. Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders. J Affect Disord 2020;274:315-25. [PMID: 32469822 DOI: 10.1016/j.jad.2020.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
120 Zhou X, Cipriani A, Furukawa TA, Cuijpers P, Zhang Y, Hetrick SE, Pu J, Yuan S, Del Giovane C, Xie P. Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis. BMJ Open. 2018;8:e018357. [PMID: 29306886 DOI: 10.1136/bmjopen-2017-018357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
121 Wang Z, Li X, Li N, Huang L, Liu J, Yang B, Shi J, Fei Y, Ji X, Gao K, Ren M. Safety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study. Front Psychiatry 2020;11:570. [PMID: 32625124 DOI: 10.3389/fpsyt.2020.00570] [Reference Citation Analysis]
122 Ciobanu AM, Dionisie V, Neagu C, Bolog OM, Riga S, Popa-Velea O. Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature. J Clin Med 2021;10:2947. [PMID: 34209089 DOI: 10.3390/jcm10132947] [Reference Citation Analysis]
123 Bayes AJ, Parker GB. Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation. Acta Psychiatr Scand 2018;137:459-71. [DOI: 10.1111/acps.12878] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
124 Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat 2018;14:567-80. [PMID: 29497300 DOI: 10.2147/NDT.S157708] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
125 Xiao L. Agomelatine for postpartum depression and breastfeeding. Ther Adv Psychopharmacol 2021;11:20451253211022172. [PMID: 34158917 DOI: 10.1177/20451253211022172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Sareen J, Holens P, Turner S, Jetly R, Kennedy S, Heisel M, Cooper K, Mota N, Comtois K, Stein MB, Schaffer A, Thompson J, Heber A. Report of the 2016 Mental Health Expert Panel on suicide prevention in the Canadian Armed Forces. Journal of Military, Veteran and Family Health 2018;4:70-89. [DOI: 10.3138/jmvfh.2017-0043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
127 Choi W, Stewart R, Kang HJ, Kim JW, Kim HK, Kang HC, Lee JY, Kim SW, Kim JM. Interactive effects of systemic inflammation and life stressors on treatment response of depressive disorders. Brain Behav Immun 2021;95:61-7. [PMID: 33548497 DOI: 10.1016/j.bbi.2021.01.029] [Reference Citation Analysis]
128 Ceresa A, Esposito CM, Buoli M. How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review. J Affect Disord 2021;281:581-9. [PMID: 33250202 DOI: 10.1016/j.jad.2020.11.111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarsdóttir K, Engeland A, Furu K, Gissler M, Havard A, Hernandez-Diaz S, Huybrechts KF, Karlstad Ø, Leinonen MK, Li J, Man KKC, Pazzagli L, Schaffer A, Schink T, Wang Z, Yu Y, Zoega H, Bröms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophr Res 2020;220:106-15. [PMID: 32295750 DOI: 10.1016/j.schres.2020.03.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
130 Borrione L, Bellini H, Razza LB, Avila AG, Baeken C, Brem AK, Busatto G, Carvalho AF, Chekroud A, Daskalakis ZJ, Deng ZD, Downar J, Gattaz W, Loo C, Lotufo PA, Martin MDGM, McClintock SM, O'Shea J, Padberg F, Passos IC, Salum GA, Vanderhasselt MA, Fraguas R, Benseñor I, Valiengo L, Brunoni AR. Precision non-implantable neuromodulation therapies: a perspective for the depressed brain. Braz J Psychiatry 2020;42:403-19. [PMID: 32187319 DOI: 10.1590/1516-4446-2019-0741] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
131 Dodd S, Bauer M, Carvalho AF, Eyre H, Fava M, Kasper S, Kennedy SH, Khoo J, Lopez Jaramillo C, Malhi GS, Mcintyre RS, Mitchell PB, Castro AMP, Ratheesh A, Severus E, Suppes T, Trivedi MH, Thase ME, Yatham LN, Young AH, Berk M. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? The World Journal of Biological Psychiatry 2021;22:483-94. [DOI: 10.1080/15622975.2020.1851052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
132 McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, Nasri F, Majeed A, Lui LMW, Senyk O, Phan L, Carvalho IP, Siegel A, Mansur RB, Brietzke E, Kratiuk K, Arekapudi AK, Abrishami A, Chau EH, Szpejda W, Rosenblat JD. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord 2020;274:903-10. [PMID: 32664031 DOI: 10.1016/j.jad.2020.05.088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
133 Yang L, Di YM, Shergis JL, Li Y, Zhang AL, Lu C, Guo X, Xue CC. A systematic review of acupuncture and Chinese herbal medicine for postpartum depression. Complementary Therapies in Clinical Practice 2018;33:85-92. [DOI: 10.1016/j.ctcp.2018.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
134 Tomaz VS, Chaves Filho AJM, Cordeiro RC, Jucá PM, Soares MVR, Barroso PN, Cristino LMF, Jiang W, Teixeira AL, de Lucena DF, Macedo DS. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 2020;268:188-200. [PMID: 32174477 DOI: 10.1016/j.jad.2020.03.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
135 Watts D, Garcia FD, Lacerda ALT, Mari JJ, Quarantini LC, Kapczinski F. Intranasal esketamine and the dawn of precision psychiatry. Braz J Psychiatry 2021:S1516-44462021005021203. [PMID: 34320126 DOI: 10.1590/1516-4446-2021-0031] [Reference Citation Analysis]
136 Al Shirawi MI, Edgar NE, Kennedy SH. Brexpiprazole in the Treatment of Major Depressive Disorder. Clinical Medicine Insights: Therapeutics 2017;9:1179559X1773180. [DOI: 10.1177/1179559x17731801] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
137 Bahji A, Hawken ER, Cabrera C, Vazquez G. Is stigma preventing knowledge translation and utilization of electroconvulsive therapy for depression? Acta Psychiatr Scand 2019;140:85-7. [DOI: 10.1111/acps.13035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Tavares DF, Suen P, Rodrigues Dos Santos CG, Moreno DH, Lane Valiengo LDC, Klein I, Borrione L, Marques Forte P, Brunoni AR, Alberto Moreno R. Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial. Neuropsychopharmacology 2021. [PMID: 34193961 DOI: 10.1038/s41386-021-01080-9] [Reference Citation Analysis]
139 Tran BX, Ha GH, Vu GT, Nguyen LH, Latkin CA, Nathan K, McIntyre RS, Ho CS, Tam WW, Ho RC. Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis. Int J Environ Res Public Health 2019;16:E2255. [PMID: 31247926 DOI: 10.3390/ijerph16132255] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
140 Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, Kim W, Shim SH, Lee JG, Jon DI, Min KJ. Korean Medication Algorithm for Depressive Disorders 2017: Third Revision. Clin Psychopharmacol Neurosci 2018;16:67-87. [PMID: 29397669 DOI: 10.9758/cpn.2018.16.1.67] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
141 Mao L, Lv FF, Yang WF, Zhang TF, Li ZC, Li DQ, Chen ZB. Effects of Baihui electroacupuncture in a rat model of depression. Ann Transl Med 2020;8:1646. [PMID: 33490158 DOI: 10.21037/atm-20-7459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Zuilhof Z, Norris S, Blondeau C, Tessier P, Blier P. Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial. Neuropsychiatr Dis Treat 2018;14:3209-18. [PMID: 30538479 DOI: 10.2147/NDT.S175203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Mosqueiro BP, Caldieraro MA, Messinger M, da Costa FBP, Peteet JR, P Fleck M. Religiosity, spirituality, suicide risk and remission of depressive symptoms: a 6-month prospective study of tertiary care Brazilian patients. J Affect Disord 2021;279:434-42. [PMID: 33120244 DOI: 10.1016/j.jad.2020.10.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Ayani N, Morimoto T, Sakuma M, Kikuchi T, Watanabe K, Narumoto J. Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study. J Clin Psychopharmacol 2021;41:397-402. [PMID: 34108429 DOI: 10.1097/JCP.0000000000001416] [Reference Citation Analysis]
145 Baldaçara L, Grudtner RR, da S Leite V, Porto DM, Robis KP, Fidalgo TM, Rocha GA, Diaz AP, Meleiro A, Correa H, Tung TC, Malloy-Diniz L, Quevedo J, da Silva AG. Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 2. Screening, intervention, and prevention. Braz J Psychiatry 2020:S1516-44462020005039201. [PMID: 33331533 DOI: 10.1590/1516-4446-2020-1108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Goodwin GM. Revisiting Treatment Options for Depressed Patients with Generalised Anxiety Disorder. Adv Ther 2021;38:61-8. [PMID: 34417993 DOI: 10.1007/s12325-021-01861-0] [Reference Citation Analysis]
147 Aşçibaşi K, Çökmüş FP, Dikici DS, Özkan HM, Alçi D, Altunsoy N, Kuru E, Yüzeren S, Aydemir Ö. Evaluation of Emotional Adverse Effects of Antidepressants: A Follow-up Study. J Clin Psychopharmacol 2020;40:594-8. [PMID: 33065720 DOI: 10.1097/JCP.0000000000001300] [Reference Citation Analysis]
148 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
149 Bares M, Brunovsky M, Stopkova P, Hejzlar M, Novak T. Transcranial Direct-Current Stimulation (tDCS) Versus Venlafaxine ER In The Treatment Of Depression: A Randomized, Double-Blind, Single-Center Study With Open-Label, Follow-Up. Neuropsychiatr Dis Treat 2019;15:3003-14. [PMID: 31695391 DOI: 10.2147/NDT.S226577] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
150 Jacobs M, Pradier MF, McCoy TH Jr, Perlis RH, Doshi-Velez F, Gajos KZ. How machine-learning recommendations influence clinician treatment selections: the example of the antidepressant selection. Transl Psychiatry 2021;11:108. [PMID: 33542191 DOI: 10.1038/s41398-021-01224-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
151 Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. CNS Spectr 2020;25:372-9. [PMID: 31120009 DOI: 10.1017/S1092852919000853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord 2021;278:542-55. [PMID: 33022440 DOI: 10.1016/j.jad.2020.09.071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
153 Cookey J. Use of MAOIs in severe treatment-resistant depression: back to the old school. J Psychiatry Neurosci 2021;46:E427-8. [PMID: 34223742 DOI: 10.1503/jpn.200214] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Chakrabarty T, McInerney SJ, Torres IJ, Frey BN, Milev RV, Müller DJ, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs 2021;35:291-304. [PMID: 33683582 DOI: 10.1007/s40263-021-00793-1] [Reference Citation Analysis]
155 Fan M, Bousman CA. Estimating the Potential Impact of CYP2C19 and CYP2D6 Genetic Testing on Protocol-Based Care for Depression in Canada and the United States. Mol Neuropsychiatry 2020;5:27-33. [PMID: 32399467 DOI: 10.1159/000504253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Archer S, Chrenek C, Swainson J. Maintenance Ketamine Therapy for Treatment-Resistant Depression. J Clin Psychopharmacol 2018;38:380-4. [DOI: 10.1097/jcp.0000000000000894] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
157 Di YM, Yang L, Shergis JL, Zhang AL, Li Y, Guo X, Xue CC, Lu C. Clinical evidence of Chinese medicine therapies for depression in women during perimenopause and menopause. Complementary Therapies in Medicine 2019;47:102071. [DOI: 10.1016/j.ctim.2019.03.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Choi KW, Na EJ, Fava M, Mischoulon D, Cho H, Jeon HJ. Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder. Psychiatry Res 2018;270:246-52. [PMID: 30269042 DOI: 10.1016/j.psychres.2018.09.047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
159 Puzhko S, Schuster T, Barnett TA, Renoux C, Rosenberg E, Barber D, Bartlett G. Evaluating Prevalence and Patterns of Prescribing Medications for Depression for Patients With Obesity Using Large Primary Care Data (Canadian Primary Care Sentinel Surveillance Network). Front Nutr 2020;7:24. [PMID: 32258046 DOI: 10.3389/fnut.2020.00024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
160 Walkery A, Leader LD, Cooke E, VandenBerg A. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders. Drug Des Devel Ther 2021;15:3017-26. [PMID: 34267503 DOI: 10.2147/DDDT.S240856] [Reference Citation Analysis]
161 Hiance-Delahaye A, de Schongor FM, Lechowski L, Teillet L, Arvieu JJ, Robine JM, Ankri J, Herr M. Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality. Int Psychogeriatr 2018;30:715-26. [PMID: 29145919 DOI: 10.1017/S1041610217002290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
162 Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P. Involvement of 5-HT1A and 5-HT2A Receptors but Not α 2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo. Mol Pharmacol 2018;94:1363-70. [PMID: 30322874 DOI: 10.1124/mol.118.113290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
163 Agorastos A, Sommer A, Heinig A, Wiedemann K, Demiralay C. Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study. Front Psychiatry 2020;11:453. [PMID: 32508691 DOI: 10.3389/fpsyt.2020.00453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Lee Y, Brietzke E, Cao B, Chen Y, Linnaranta O, Mansur RB, Cortes P, Kösters M, Majeed A, Tamura JK, Lui LMW, Vinberg M, Keinänen J, Kisely S, Naveed S, Barbui C, Parker G, Owolabi M, Nishi D, Lee J, Srisurapanont M, Gill H, Guo L, Balanzá-Martínez V, Partonen T, Nolen WA, Lee JH, Kim JH, Chavannes NH, Ewais T, Atienza-Carbonell B, Silven AV, Yasuma N, Gil A, Novikov A, Lacey C, Versluis A, von Malortie S, Chan LF, Waqas A, Purgato M, Aardoom JJ, Ly-Uson JT, Sim K, Tuineag M, van der Kleij RMJJ, van Luenen S, Suttajit S, Hajek T, Lee YW, Porter RJ, Alsuwaidan M, Rosenblat JD, Ravindran AV, Lam RW, McIntyre RS; Global Alliance for Chronic Diseases (GACD) Mental Health Guidelines Working Group. Development and implementation of guidelines for the management of depression: a systematic review. Bull World Health Organ 2020;98:683-697H. [PMID: 33177758 DOI: 10.2471/BLT.20.251405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
165 Elder K, Turner KA, Cosgrove L, Lexchin J, Shnier A, Moore A, Straus S, Thombs BD. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ 2020;192:E617-25. [PMID: 32538799 DOI: 10.1503/cmaj.191737] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
166 Dionisie V, Ciobanu AM, Toma VA, Manea MC, Baldea I, Olteanu D, Sevastre-Berghian A, Clichici S, Manea M, Riga S, Filip GA. Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress. Int J Mol Sci 2021;22:7483. [PMID: 34299103 DOI: 10.3390/ijms22147483] [Reference Citation Analysis]
167 McIntyre RS, Young AH, Haddad PM. Rethinking the spectrum of mood disorders: implications for diagnosis and management - Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. Ther Adv Psychopharmacol 2018;8:1-16. [PMID: 29977518 DOI: 10.1177/2045125318762911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
168 Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel) 2021;11:765. [PMID: 34440508 DOI: 10.3390/life11080765] [Reference Citation Analysis]
169 Bhat V, Kennedy SH. Recognition and management of antidepressant discontinuation syndrome. J Psychiatry Neurosci 2017;42:E7-8. [PMID: 28639936 DOI: 10.1503/jpn.170022] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
170 Thase ME. New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectr 2017;22:39-48. [DOI: 10.1017/s1092852917000876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
171 Kleinerman A, Rosenfeld A, Benrimoh D, Fratila R, Armstrong C, Mehltretter J, Shneider E, Yaniv-Rosenfeld A, Karp J, Reynolds CF, Turecki G, Kapelner A. Treatment selection using prototyping in latent-space with application to depression treatment. PLoS One 2021;16:e0258400. [PMID: 34767577 DOI: 10.1371/journal.pone.0258400] [Reference Citation Analysis]
172 Lara LADS, Scalco SCP, Rufino AC, Paula SRC, Fernandes ES, Pereira JML, França SS, Reis S, Almeida SB, Vale FBC, Lerner T, Carvalho YMV, Abdo CHN, Oliveira FFL. Management of hypoactive sexual desire disorder in women in the gynecological setting. Rev Bras Ginecol Obstet 2021;43:417-24. [PMID: 34182585 DOI: 10.1055/s-0041-1731410] [Reference Citation Analysis]
173 Puzhko S, Aboushawareb SA, Kudrina I, Schuster T, Barnett TA, Renoux C, Bartlett G. Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. Journal of Affective Disorders 2020;267:153-70. [DOI: 10.1016/j.jad.2020.01.113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
174 Mischoulon D, Nyer M, Raison C. Commentary on: "Association Between Passive Body Heating by Hot Water Bathing Before Bedtime and Depressive Symptoms Among Community-Dwelling Older Adults". Am J Geriatr Psychiatry 2021:S1064-7481(21)00390-0. [PMID: 34348853 DOI: 10.1016/j.jagp.2021.07.004] [Reference Citation Analysis]
175 Cadarette SM, Maclure M, Delaney JAC, Whitaker HJ, Hayes KN, Wang SV, Tadrous M, Gagne JJ, Consiglio GP, Hallas J. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2021;30:671-84. [PMID: 33715267 DOI: 10.1002/pds.5227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
176 Vázquez GH, Lolich M, Cabrera C, Jokic R, Kolar D, Tondo L, Baldessarini RJ. Mixed symptoms in major depressive and bipolar disorders: A systematic review. Journal of Affective Disorders 2018;225:756-60. [DOI: 10.1016/j.jad.2017.09.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
177 Ross EL, Soeteman DI. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatr Serv 2020;71:988-97. [PMID: 32631129 DOI: 10.1176/appi.ps.201900625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
178 Katzman MA, Wang X, Wajsbrot DB, Boucher M. Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. J Psychopharmacol 2020;34:280-92. [DOI: 10.1177/0269881119896066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
179 Guillaumie L, Ndayizigiye A, Beaucage C, Moisan J, Grégoire JP, Villeneuve D, Lauzier S. Patient perspectives on the role of community pharmacists for antidepressant treatment: A qualitative study. Can Pharm J (Ott) 2018;151:142-8. [PMID: 29531632 DOI: 10.1177/1715163518755814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
180 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
181 Tundo A, Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta‐analysis. Acta Psychiatr Scand 2019;140:116-25. [DOI: 10.1111/acps.13055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
182 Bozymski KM, Crouse EL, Titus-lay EN, Ott CA, Nofziger JL, Kirkwood CK. Esketamine: A Novel Option for Treatment-Resistant Depression. Ann Pharmacother 2020;54:567-76. [DOI: 10.1177/1060028019892644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
183 Thomson M, Sharma V. Pharmacotherapeutic considerations for the treatment of posttraumatic stress disorder during and after pregnancy. Expert Opin Pharmacother 2021;22:705-14. [PMID: 33225773 DOI: 10.1080/14656566.2020.1854727] [Reference Citation Analysis]
184 Woo YS, Lim HK, Wang SM, Bahk WM. Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review. Int J Mol Sci 2020;21:E6969. [PMID: 32971941 DOI: 10.3390/ijms21186969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
185 Thase ME, Stanford AD, Memisoglu A, Martin W, Claxton A, Bodkin JA, Trivedi MH, Fava M, Yu M, Pathak S. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. Neuropsychopharmacology 2019;44:2268-76. [PMID: 31254971 DOI: 10.1038/s41386-019-0451-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
186 Keating LE, Becker S, McCabe K, Whattam J, Garrick L, Frey BN, Sassi RB, McKinnon MC. Impact of a structured, group-based running programme on clinical, cognitive and social function in youth and adults with complex mood disorders: a 12-week pilot study. BMJ Open Sport Exerc Med 2019;5:e000521. [PMID: 31191972 DOI: 10.1136/bmjsem-2019-000521] [Reference Citation Analysis]
187 Tanguay-Sela M, Benrimoh D, Popescu C, Perez T, Rollins C, Snook E, Lundrigan E, Armstrong C, Perlman K, Fratila R, Mehltretter J, Israel S, Champagne M, Williams J, Simard J, Parikh SV, Karp JF, Heller K, Linnaranta O, Cardona LG, Turecki G, Margolese HC. Evaluating the perceived utility of an artificial intelligence-powered clinical decision support system for depression treatment using a simulation center. Psychiatry Res 2021;308:114336. [PMID: 34953204 DOI: 10.1016/j.psychres.2021.114336] [Reference Citation Analysis]
188 Talbot J, Phillips JL, Blier P. Ketamine for chronic depression: two cautionary tales. J Psychiatry Neurosci 2019;44:384-5. [PMID: 31573153 DOI: 10.1503/jpn.190073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
189 Carpenter JS, Crouse JJ, Scott EM, Naismith SL, Wilson C, Scott J, Merikangas KR, Hickie IB. Circadian depression: A mood disorder phenotype. Neurosci Biobehav Rev 2021;126:79-101. [PMID: 33689801 DOI: 10.1016/j.neubiorev.2021.02.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
190 Fornaro M, De Berardis D, Anastasia A, Fusco A. "Novel Psychopharmacology for Depressive Disorders". Adv Exp Med Biol 2021;1305:449-61. [PMID: 33834412 DOI: 10.1007/978-981-33-6044-0_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol 2019;22:698-709. [PMID: 31350882 DOI: 10.1093/ijnp/pyz040] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 McCradden MD. When is accuracy off-target? Transl Psychiatry 2021;11:369. [PMID: 34226492 DOI: 10.1038/s41398-021-01479-4] [Reference Citation Analysis]
193 Currie JM, Macleod WB. UNDERSTANDING DOCTOR DECISION MAKING: THE CASE OF DEPRESSION TREATMENT. Econometrica 2020;88:847-78. [PMID: 32981946 DOI: 10.3982/ecta16591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
194 Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. J Clin Psychopharmacol 2017;37:555-61. [PMID: 28817491 DOI: 10.1097/JCP.0000000000000775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Liu Y, Dai D, Huang K, Zhuang R, Ma L, Liu B, Pan Y, Zhang L. The efficacy and safety of acupuncture for patients with post-percutaneous coronary intervention depression: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e23510. [PMID: 33327293 DOI: 10.1097/MD.0000000000023510] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Wang Y, Shi Y, Xu Z, Fu H, Zeng H, Zheng G. Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research 2019;117:74-91. [DOI: 10.1016/j.jpsychires.2019.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
197 Lunsky Y, Khuu W, Tadrous M, Vigod S, Cobigo V, Gomes T. Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. Can J Psychiatry 2018;63:361-9. [PMID: 28830241 DOI: 10.1177/0706743717727240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
198 Ross EL, Zivin K, Maixner DF. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States. JAMA Psychiatry 2018;75:713-22. [PMID: 29800956 DOI: 10.1001/jamapsychiatry.2018.0768] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 15.7] [Reference Citation Analysis]
199 Zhou L, Zhu Y, Chen W, Tang Y. Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response. J Affect Disord 2021;286:80-6. [PMID: 33714174 DOI: 10.1016/j.jad.2021.02.063] [Reference Citation Analysis]
200 Carvalho Henriques B, Yang EH, Lapetina D, Carr MS, Yavorskyy V, Hague J, Aitchison KJ. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? Front Genet 2020;11:491895. [PMID: 33363564 DOI: 10.3389/fgene.2020.491895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
201 Vos CF, Aarnoutse RE, Op de Coul MJM, Spijker J, Groothedde-Kuyvenhoven MM, Mihaescu R, Wessels-Basten SJW, Rovers JJE, Ter Hark SE, Schene AH, Hulscher MEJL, Janzing JGE. Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands. BMC Psychiatry 2021;21:481. [PMID: 34598683 DOI: 10.1186/s12888-021-03490-x] [Reference Citation Analysis]
202 Malas N, Plioplys S, Pao M. Depression in Medically Ill Children and Adolescents. Child Adolesc Psychiatr Clin N Am 2019;28:421-45. [PMID: 31076118 DOI: 10.1016/j.chc.2019.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Mulder R, Hamilton A, Irwin L, Boyce P, Morris G, Porter RJ, Malhi GS. Treating depression with adjunctive antipsychotics. Bipolar Disord 2018;20:17-24. [DOI: 10.1111/bdi.12701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
204 Zhou J, Liu S, Mayes TL, Feng Y, Fang M, Xiao L, Wang G. The network analysis of depressive symptoms before and after two weeks of antidepressant treatment. J Affect Disord 2021;299:126-34. [PMID: 34838606 DOI: 10.1016/j.jad.2021.11.059] [Reference Citation Analysis]
205 Hori H, Yamato K. Assessment of current clinical practices for major depression in Japan using a web-based questionnaire. Neuropsychiatr Dis Treat 2019;15:2821-32. [PMID: 31632030 DOI: 10.2147/NDT.S217098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
206 Lopizzo N, Zonca V, Cattane N, Pariante CM, Cattaneo A. miRNAs in depression vulnerability and resilience: novel targets for preventive strategies. J Neural Transm (Vienna) 2019;126:1241-58. [PMID: 31350592 DOI: 10.1007/s00702-019-02048-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
207 Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, Chakrabarty T, Frey BN, Milev RV, Müller DJ, Parikh SV, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. Pharmacopsychiatry 2021;54:225-31. [PMID: 33652477 DOI: 10.1055/a-1385-0263] [Reference Citation Analysis]
208 Magalhães EJM, Sarin LM, Del Sant LC, Lucchese AC, Nakahira C, Tuena MA, Puertas CB, Rodovalho Fava VA, Delfino RS, Surjan J, Steglich MS, Barbosa MG, Abdo G, Del Porto JA, Nemeroff CB, Cogo-Moreira H, Lacerda ALT, Mello AF. A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression. Front Psychiatry 2021;12:608499. [PMID: 34483976 DOI: 10.3389/fpsyt.2021.608499] [Reference Citation Analysis]
209 Ju C, Fiori LM, Belzeaux R, Theroux JF, Chen GG, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW, Leri F, MacQueen GM, Milev R, Müller DJ, Parikh SV, Rotzinger S, Soares CN, Uher R, Li Q, Foster JA, Kennedy SH, Turecki G. Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Transl Psychiatry 2019;9:254. [PMID: 31594917 DOI: 10.1038/s41398-019-0589-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
210 Uthayakumar S, Tadrous M, Vigod SN, Kitchen SA, Gomes T. The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. Depress Anxiety 2021. [PMID: 34843627 DOI: 10.1002/da.23228] [Reference Citation Analysis]
211 Albert PR. Influence of functional gene polymorphisms on human behaviour: the case of CCR5. J Psychiatry Neurosci 2021;46:E659-62. [PMID: 34916235 DOI: 10.1503/jpn.210197] [Reference Citation Analysis]
212 Liu W, Rao C, Zhao Q, Du Y, Nan X, Li Z, Yin C. Effectiveness and safety of manual acupuncture therapy in patients with post-stroke depression: a protocol for a systematic review and meta-analysis. BMJ Open 2021;11:e048686. [PMID: 34893483 DOI: 10.1136/bmjopen-2021-048686] [Reference Citation Analysis]
213 Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH. Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neurosci Ther 2018;24:615-23. [PMID: 29687627 DOI: 10.1111/cns.12854] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
214 Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110266. [PMID: 33549697 DOI: 10.1016/j.pnpbp.2021.110266] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
215 Tamblyn R, Bates DW, Buckeridge DL, Dixon W, Forster AJ, Girard N, Haas J, Habib B, Kurteva S, Li J, Sheppard T. Multinational comparison of new antidepressant use in older adults: a cohort study. BMJ Open 2019;9:e027663. [PMID: 31092665 DOI: 10.1136/bmjopen-2018-027663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
216 Kolar D. Addictive potential of novel treatments for refractory depression and anxiety. Neuropsychiatr Dis Treat 2018;14:1513-9. [PMID: 29928123 DOI: 10.2147/NDT.S167538] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
217 Jhon M, Stewart R, Kim JW, Kang HJ, Lee JY, Kim SW, Shin IS, Kim JM. Predictors and outcomes of experienced and anticipated discrimination in patients treated for depression: A 2-year longitudinal study. J Affect Disord 2021;294:761-8. [PMID: 34375201 DOI: 10.1016/j.jad.2021.07.049] [Reference Citation Analysis]
218 Jessel CD, Mostafa S, Potiriadis M, Everall IP, Gunn JM, Bousman CA. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. Pharmacogenetics and Genomics 2020;30:145-52. [DOI: 10.1097/fpc.0000000000000406] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Ravindran AV, McKay MS, Silva TD, Tindall C, Garfinkel T, Paric A, Ravindran L. Breathing-focused Yoga as Augmentation for Unipolar and Bipolar Depression: A Randomized Controlled Trial: Le yoga axé sur la respiration comme traitement d'appoint pour la dépression unipolaire et bipolaire: Un essai randomisé contrôlé. Can J Psychiatry 2021;66:159-69. [PMID: 32677851 DOI: 10.1177/0706743720940535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 Akechi T, Mantani A, Kurata K, Hirota S, Shimodera S, Yamada M, Inagaki M, Watanabe N, Kato T, Furukawa TA; SUND Investigators. Predicting relapse in major depression after successful initial pharmacological treatment. J Affect Disord 2019;250:108-13. [PMID: 30851699 DOI: 10.1016/j.jad.2019.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
221 Kang HJ, Kim JW, Kim SY, Kim SW, Shin HY, Shin MG, Kim JM. The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology. Psychiatry Investig 2018;15:538-45. [PMID: 29614851 DOI: 10.30773/pi.2017.10.2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
222 Dai CX, Hu CC, Shang YS, Xie J. Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B. Medicine (Baltimore) 2018;97:e12421. [PMID: 30278520 DOI: 10.1097/MD.0000000000012421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
223 Ng JY, Nazir Z, Nault H. Complementary and alternative medicine recommendations for depression: a systematic review and assessment of clinical practice guidelines. BMC Complement Med Ther 2020;20:299. [PMID: 33028320 DOI: 10.1186/s12906-020-03085-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
224 Scotti-Muzzi E, Chile T, Moreno R, Pastorello BF, da Costa Leite C, Henning A, Otaduy MCG, Vallada H, Soeiro-de-Souza MG. ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization. Eur Arch Psychiatry Clin Neurosci 2021;271:537-47. [PMID: 31993746 DOI: 10.1007/s00406-020-01096-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Keks NA, Hope J, Keogh S, Copolov DL. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant. Australas Psychiatry 2018;26:537-40. [DOI: 10.1177/1039856218794874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, McInerney S, Chakrabarty T, Frey BN, Milev RV, Müller DJ, Parikh SV, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs 2021;35:439-50. [PMID: 33860922 DOI: 10.1007/s40263-021-00803-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
228 Soares CN, Wajsbrot DB, Boucher M. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder. CNS Spectr 2020;25:363-71. [PMID: 31060632 DOI: 10.1017/S1092852919000828] [Reference Citation Analysis]
229 Gloster AT, Rinner MT, Ioannou M, Villanueva J, Block VJ, Ferrari G, Benoy C, Bader K, Karekla M. Treating treatment non-responders: A meta-analysis of randomized controlled psychotherapy trials. Clinical Psychology Review 2020;75:101810. [DOI: 10.1016/j.cpr.2019.101810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
230 Akechi T, Sugishita K, Chino B, Itoh K, Ikeda Y, Shimodera S, Yonemoto N, Miki K, Ogawa Y, Takeshima N, Kato T, Furukawa TA. Whose depression deteriorates during acute phase antidepressant treatment? Journal of Affective Disorders 2020;260:342-8. [DOI: 10.1016/j.jad.2019.09.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 Dionisie V, Filip GA, Manea MC, Manea M, Riga S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology 2021;29:75-90. [PMID: 33164143 DOI: 10.1007/s10787-020-00777-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
232 Rosenblat JD, Kurdyak P, Cosci F, Berk M, Maes M, Brunoni AR, Li M, Rodin G, McIntyre RS, Carvalho AF. Depression in the medically ill. Aust N Z J Psychiatry 2020;54:346-66. [PMID: 31749372 DOI: 10.1177/0004867419888576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
233 Wu Y, Mo J, Sui L, Zhang J, Hu W, Zhang C, Wang Y, Liu C, Zhao B, Wang X, Zhang K, Xie X. Deep Brain Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis on Efficacy and Safety. Front Neurosci 2021;15:655412. [PMID: 33867929 DOI: 10.3389/fnins.2021.655412] [Reference Citation Analysis]
234 Liew TM, Lee CS. Comparative efficacy and acceptability of interventions for major depression in older persons: protocol for Bayesian network meta-analysis. BMJ Open 2018;8:e019819. [PMID: 29358451 DOI: 10.1136/bmjopen-2017-019819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
235 Desbeaumes Jodoin V, Miron J, Lespérance P. Safety and Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation Protocol in Elderly Depressed Unipolar and Bipolar Patients. The American Journal of Geriatric Psychiatry 2019;27:548-58. [DOI: 10.1016/j.jagp.2018.10.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
236 Nogovitsyn N, Muller M, Souza R, Hassel S, Arnott SR, Davis AD, Hall GB, Harris JK, Zamyadi M, Metzak PD, Ismail Z, Downar J, Parikh SV, Soares CN, Addington JM, Milev R, Harkness KL, Frey BN, Lam RW, Strother SC, Rotzinger S, Kennedy SH, MacQueen GM. Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology 2020;45:283-91. [PMID: 31610545 DOI: 10.1038/s41386-019-0542-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
237 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
238 Castaldelli-Maia JM, Hofmann C, Chagas ACP, Liprandi AS, Alcocer A, Andrade LH, Wielgosz A. Major Cardiac-Psychiatric Drug-Drug Interactions: a Systematic Review of the Consistency of Drug Databases. Cardiovasc Drugs Ther 2021;35:441-54. [PMID: 32424652 DOI: 10.1007/s10557-020-06979-x] [Reference Citation Analysis]
239 Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol 2019;22:616-30. [PMID: 31290965 DOI: 10.1093/ijnp/pyz039] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 50.5] [Reference Citation Analysis]
240 Mangin D, Lawson J, Cuppage J, Shaw E, Ivanyi K, Davis A, Risdon C. Legacy Drug-Prescribing Patterns in Primary Care. Ann Fam Med 2018;16:515-20. [PMID: 30420366 DOI: 10.1370/afm.2315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
241 Laplace B, Calvet B, Lacroix A, Mouchabac S, Picard N, Girard M, Charles E. Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey. J Pers Med 2021;11:446. [PMID: 34064030 DOI: 10.3390/jpm11060446] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
242 Thom RP, Pober BR, McDougle CJ. Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness. Expert Opin Drug Saf 2021;20:293-306. [PMID: 33369485 DOI: 10.1080/14740338.2021.1867535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 De Crescenzo F, Garriga C, Tomlinson A, Coupland C, Efthimiou O, Fazel S, Hippisley-Cox J, Cipriani A. Real-world effect of antidepressants for depressive disorder in primary care: protocol of a population-based cohort study. Evid Based Ment Health 2020;23:122-6. [PMID: 32554440 DOI: 10.1136/ebmental-2020-300149] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. J Affect Disord 2021;292:416-23. [PMID: 34144366 DOI: 10.1016/j.jad.2021.05.119] [Reference Citation Analysis]
245 Thériault FL, Garber BG, Momoli F, Gardner W, Zamorski MA, Colman I. Mental Health Service Utilization in Depressed Canadian Armed Forces Personnel. Can J Psychiatry 2019;64:59-67. [PMID: 30016882 DOI: 10.1177/0706743718787792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
246 Subermaniam K, Yow YY, Lim SH, Koh OH, Wong KH. Malaysian macroalga Padina australis Hauck attenuates high dose corticosterone-mediated oxidative damage in PC12 cells mimicking the effects of depression. Saudi J Biol Sci 2020;27:1435-45. [PMID: 32489279 DOI: 10.1016/j.sjbs.2020.04.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, Brown K, Jablonski MR, Dechairo B. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics 2020;21:559-69. [PMID: 32301649 DOI: 10.2217/pgs-2019-0157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
248 Kowalczyk M, Kowalczyk E, Kwiatkowski P, Łopusiewicz Ł, Talarowska M, Sienkiewicz M. Cellular Response to Unfolded Proteins in Depression. Life (Basel) 2021;11:1376. [PMID: 34947907 DOI: 10.3390/life11121376] [Reference Citation Analysis]
249 Patten SB. Updated CANMAT Guidelines for Treatment of Major Depressive Disorder. Can J Psychiatry 2016;61:504-5. [PMID: 27534886 DOI: 10.1177/0706743716660034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
250 Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry 2021;66:113-25. [PMID: 33174760 DOI: 10.1177/0706743720970860] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
251 Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? J Psychiatr Pract 2021;27:361-71. [PMID: 34529602 DOI: 10.1097/PRA.0000000000000578] [Reference Citation Analysis]
252 Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 2019;53:109-18. [PMID: 30378447 DOI: 10.1177/0004867418808585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
253 Vigo D, Haro JM, Hwang I, Aguilar-Gaxiola S, Alonso J, Borges G, Bruffaerts R, Caldas-de-Almeida JM, de Girolamo G, Florescu S, Gureje O, Karam E, Karam G, Kovess-Masfety V, Lee S, Navarro-Mateu F, Ojagbemi A, Posada-Villa J, Sampson NA, Scott K, Stagnaro JC, Ten Have M, Viana MC, Wu CS, Chatterji S, Cuijpers P, Thornicroft G, Kessler RC. Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder. Psychol Med 2020;:1-11. [PMID: 33077023 DOI: 10.1017/S0033291720003797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ. Medication use and kidney cancer risk: A population-based study. European Journal of Cancer 2017;83:203-10. [DOI: 10.1016/j.ejca.2017.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
255 Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry 2017;59:S34-50. [PMID: 28216784 DOI: 10.4103/0019-5545.196973] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
256 Shim IH, Woo YS, Kim MD, Bahk WM. Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression. Int J Mol Sci 2017;18:E2406. [PMID: 29137178 DOI: 10.3390/ijms18112406] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
257 Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord 2018;241:484-91. [PMID: 30149336 DOI: 10.1016/j.jad.2018.08.056] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
258 Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, Nemeroff CB, McDonald WM, Kalin NH; APA Council of Research Task Force on Novel Biomarkers and Treatments. Hormonal Treatments for Major Depressive Disorder: State of the Art. Am J Psychiatry 2020;177:686-705. [PMID: 32456504 DOI: 10.1176/appi.ajp.2020.19080848] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
259 Wang MZ, Jha MK, Minhajuddin A, Pipes R, Levinson S, Mayes TL, Greer TL, Trivedi MH. A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. Gen Hosp Psychiatry 2021;74:1-8. [PMID: 34784574 DOI: 10.1016/j.genhosppsych.2021.11.001] [Reference Citation Analysis]
260 Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT; and the VAST-D Investigators. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017;318:132-45. [PMID: 28697253 DOI: 10.1001/jama.2017.8036] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
261 Cheng T. Late-Life Depression. In: Hategan A, Bourgeois JA, Hirsch CH, Giroux C, editors. Geriatric Psychiatry. Cham: Springer International Publishing; 2018. pp. 219-35. [DOI: 10.1007/978-3-319-67555-8_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
262 Popescu C, Golden G, Benrimoh D, Tanguay-Sela M, Slowey D, Lundrigan E, Williams J, Desormeau B, Kardani D, Perez T, Rollins C, Israel S, Perlman K, Armstrong C, Baxter J, Whitmore K, Fradette MJ, Felcarek-Hope K, Soufi G, Fratila R, Mehltretter J, Looper K, Steiner W, Rej S, Karp JF, Heller K, Parikh SV, McGuire-Snieckus R, Ferrari M, Margolese H, Turecki G. Evaluating the Clinical Feasibility of an Artificial Intelligence-Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study. JMIR Form Res 2021;5:e31862. [PMID: 34694234 DOI: 10.2196/31862] [Reference Citation Analysis]
263 Rao C, Liu W, Li Z, Nan X, Yin C, Yang J, Du Y. The comparison of different acupuncture therapies for post stroke depression: A protocol for a Bayesian network meta-analysis. Medicine (Baltimore) 2020;99:e23456. [PMID: 33350728 DOI: 10.1097/MD.0000000000023456] [Reference Citation Analysis]
264 Choi W, Kim JW, Kang HJ, Kim HK, Kang HC, Lee JY, Kim SW, Stewart R, Kim JM. Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders. Sci Rep 2021;11:24226. [PMID: 34930976 DOI: 10.1038/s41598-021-03753-3] [Reference Citation Analysis]
265 Keating LE, Becker S, McCabe K, Whattam J, Garrick L, Sassi RB, Frey BN, McKinnon MC. Effects of a 12-week running programme in youth and adults with complex mood disorders. BMJ Open Sport Exerc Med 2018;4:e000314. [PMID: 29955373 DOI: 10.1136/bmjsem-2017-000314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
266 Xiao M, Feng L, Wang Q, Luan X, Chen S, He J. The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Int J Geriatr Psychiatry 2021;36:182-9. [PMID: 32830332 DOI: 10.1002/gps.5412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Karrouri R, Hammani Z, Benjelloun R, Otheman Y. Major depressive disorder: Validated treatments and future challenges. World J Clin Cases 2021; 9(31): 9350-9367 [PMID: 34877271 DOI: 10.12998/wjcc.v9.i31.9350] [Reference Citation Analysis]
268 Reutfors J, Brenner P, Brody B, Wray H, Andersen M, Brandt L. A Post-Authorization Safety Study of Quetiapine as Antidepressant Treatment in Sweden: Nested Case-Control Analyses of Select Outcomes. Drug Saf 2020;43:135-45. [PMID: 31848933 DOI: 10.1007/s40264-019-00889-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
269 Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, Drevets W. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: A phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol 2021:pyab050. [PMID: 34324636 DOI: 10.1093/ijnp/pyab050] [Reference Citation Analysis]
270 Smetanka A, Stara V, Farsky I, Tonhajzerova I, Ondrejka I. Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction. Physiol Int 2019;106:59-69. [PMID: 30888217 DOI: 10.1556/2060.106.2019.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
271 Caldieraro MA, Laufer-Silva T, Cassano P. Dosimetry and Clinical Efficacy of Transcranial Photobiomodulation for Major Depression Disorder: Could they Guide Dosimetry for Alzheimer's Disease? J Alzheimers Dis 2021;83:1453-69. [PMID: 34487045 DOI: 10.3233/JAD-210586] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Shinohara K, Efthimiou O, Ostinelli EG, Tomlinson A, Geddes JR, Nierenberg AA, Ruhe HG, Furukawa TA, Cipriani A. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. BMJ Open 2019;9:e027574. [PMID: 31110100 DOI: 10.1136/bmjopen-2018-027574] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
273 Giakoumatos CI, Osser D. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression. Harv Rev Psychiatry 2019;27:33-52. [DOI: 10.1097/hrp.0000000000000197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
274 Tursic A, Eck J, Lührs M, Linden DEJ, Goebel R. A systematic review of fMRI neurofeedback reporting and effects in clinical populations. Neuroimage Clin 2020;28:102496. [PMID: 33395987 DOI: 10.1016/j.nicl.2020.102496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
275 Daengruan P, Chairat R, Jenraumjit R, Chinwong D, Oon-Arom A, Klaphajone J, Arunmanakul P. Effectiveness of Receptive Music Therapy with Imbedded 10 Hz Binaural Beats Compared with Standard Care for Patients with Major Depressive Disorder: A Randomized Controlled Trial. Complement Ther Med 2021;61:102765. [PMID: 34375712 DOI: 10.1016/j.ctim.2021.102765] [Reference Citation Analysis]
276 Dell'Osso B, Albert U, Carrà G, Pompili M, Nanni MG, Pasquini M, Poloni N, Raballo A, Sambataro F, Serafini G, Viganò C, Demyttenaere K, McIntyre RS, Fiorillo A. How to improve adherence to antidepressant treatments in patients with major depression: a psychoeducational consensus checklist. Ann Gen Psychiatry 2020;19:61. [PMID: 33062034 DOI: 10.1186/s12991-020-00306-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Aucoin M, Cooley K, Anand L, Furtado M, Canzonieri A, Fine A, Fotinos K, Chandrasena R, Klassen LJ, Epstein I, Wood W, Katzman MA. Adjunctive Vitamin D in the treatment of non-remitted depression: Lessons from a failed clinical trial. Complement Ther Med 2018;36:38-45. [PMID: 29458928 DOI: 10.1016/j.ctim.2017.09.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
278 Park JH, Lim SW, Myung W, Park I, Jang HJ, Kim S, Lee MS, Chang HS, Yum D, Suh YL, Kim JW, Kim DK. Whole-genome sequencing reveals KRTAP1-1 as a novel genetic variant associated with antidepressant treatment outcomes. Sci Rep 2021;11:4552. [PMID: 33633223 DOI: 10.1038/s41598-021-83887-6] [Reference Citation Analysis]
279 Kuo CY, Lin CH, Lane HY. Molecular Basis of Late-Life Depression. Int J Mol Sci 2021;22:7421. [PMID: 34299040 DOI: 10.3390/ijms22147421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Li M, Chen Z, Liu Z, Zhang N, Liu J, Wang H, Wang W, Liang Y, Chen J, Liu Z, Li Y, Zhai S. Twelve Chinese herbal preparations for the treatment of depression or depressive symptoms in cancer patients: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Altern Med 2019;19:28. [PMID: 30674300 DOI: 10.1186/s12906-019-2441-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
281 Cui J, Wang Y, Liu R, Chen X, Zhang Z, Feng Y, Zhou J, Zhou Y, Wang G. Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder. Transl Psychiatry 2021;11:634. [PMID: 34903712 DOI: 10.1038/s41398-021-01754-4] [Reference Citation Analysis]
282 Borentain S, Nash AI, Dayal R, DiBernardo A. Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform. BMC Psychiatry 2020;20:384. [PMID: 32703173 DOI: 10.1186/s12888-020-02758-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Maruf AA, Poweleit EA, Brown LC, Strawn JR, Bousman CA. Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders. Pharmacopsychiatry 2021. [PMID: 34794190 DOI: 10.1055/a-1681-2047] [Reference Citation Analysis]
284 Severe J, Greden JF, Reddy P. Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe? Focus (Am Psychiatr Publ) 2020;18:120-8. [PMID: 33162849 DOI: 10.1176/appi.focus.20200008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 Cao B, Xu L, Chen Y, Wang D, Lee Y, Rosenblat JD, Gao X, Zhan S, Sun F, McIntyre RS. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectr 2021;:1-9. [PMID: 33583460 DOI: 10.1017/S1092852921000171] [Reference Citation Analysis]
286 Dinoff A, Lynch ST, Sekhri N, Klepacz L. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. Journal of Affective Disorders 2020;271:91-9. [DOI: 10.1016/j.jad.2020.03.089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Gill H, Gill B, El‐halabi S, Chen‐li D, Lipsitz O, Rosenblat JD, Van Rheenen TE, Rodrigues NB, Mansur RB, Majeed A, Lui LMW, Nasri F, Lee Y, Mcintyre RS. Antidepressant Medications and Weight Change: A Narrative Review. Obesity 2020;28:2064-72. [DOI: 10.1002/oby.22969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
288 Herniman SE, Wood SJ, Cotton SM, Allott KA, Davey C, Berk M, Phillips LJ; PROGR-S Investigators. The specific phenotype of depression in recent onset schizophrenia spectrum disorders: A symptom profile and network comparison to recent onset major depressive disorder without psychotic features. Schizophr Res 2021;240:52-60. [PMID: 34942537 DOI: 10.1016/j.schres.2021.11.048] [Reference Citation Analysis]
289 Abousheishaa AA, Lazim NHM, Tang SL, Sulaiman AH, Huri HZ, Guan NC. Antidepressant decision aid for major depressive disorder patients (ADAM): Development and pilot testing. Patient Educ Couns 2021:S0738-3991(21)00723-0. [PMID: 34844812 DOI: 10.1016/j.pec.2021.11.007] [Reference Citation Analysis]
290 Zimmerman M, Balling C, Chelminski I, Dalrymple K. Symptom presence versus symptom intensity in understanding the severity of depression: Implications for documentation in electronic medical records. J Affect Disord 2019;256:344-7. [PMID: 31207558 DOI: 10.1016/j.jad.2019.05.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
291 Fonseka TM, Pong JT, Kcomt A, Kennedy SH, Parikh SV. Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE-D co-design process. J Eval Clin Pract 2020;26:1259-69. [PMID: 31729117 DOI: 10.1111/jep.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
292 Christensen MC, Wong CMJ, Baune BT. Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ? Front Psychiatry 2020;11:280. [PMID: 32390877 DOI: 10.3389/fpsyt.2020.00280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Yuan H, Zhu X, Luo Q, Halim A, Halim M, Yao H, Cai Y, Shi S. Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study. Neuropsychiatr Dis Treat 2019;15:957-66. [PMID: 31354272 DOI: 10.2147/NDT.S196533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
294 Cao ZY, Liu YZ, Li JM, Ruan YM, Yan WJ, Zhong SY, Zhang T, Liu LL, Wu R, Wang B, Wang W, Bi XY, Wang YX, Su WJ, Jiang CL. Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial.J Affect Disord. 2020;265:247-254. [PMID: 32090748 DOI: 10.1016/j.jad.2020.01.048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
295 Schulze L, Remington G, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J. Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. J Psychopharmacol 2017;31:312-9. [DOI: 10.1177/0269881116675516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
296 Baune BT, Falkai P. Changes in antidepressant therapy should be considered early in patients with inadequate response to a first-line agent. Aust N Z J Psychiatry 2021;55:1033-8. [PMID: 33111538 DOI: 10.1177/0004867420968912] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Tavares DF, Dos Santos CGR, Valiengo LDCL, Klein I, Borrione L, Forte PM, Brunoni AR, Moreno RA. Efficacy, Safety, and Tolerability of Theta-Burst Stimulation in Mixed Depression: Design, Rationale, and Objectives of a Randomized, Double-Blinded, Sham-Controlled Trial. Front Psychiatry 2020;11:435. [PMID: 32499730 DOI: 10.3389/fpsyt.2020.00435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
298 Kato M, Asami Y, Wajsbrot DB, Wang X, Boucher M, Prieto R, Pappadopulos E. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. J Psychiatr Res 2020;129:160-7. [PMID: 32912597 DOI: 10.1016/j.jpsychires.2020.06.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
299 Zimmerman M. Severity and the Treatment of Depression: A Review of Two Controversies. J Nerv Ment Dis 2019;207:219-23. [PMID: 30920477 DOI: 10.1097/NMD.0000000000000960] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
300 Bennabi D, Charpeaud T, Yrondi A, Genty JB, Destouches S, Lancrenon S, Alaïli N, Bellivier F, Bougerol T, Camus V, Dorey JM, Doumy O, Haesebaert F, Holtzmann J, Lançon C, Lefebvre M, Moliere F, Nieto I, Rabu C, Richieri R, Schmitt L, Stephan F, Vaiva G, Walter M, Leboyer M, El-Hage W, Llorca PM, Courtet P, Aouizerate B, Haffen E. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry 2019;19:262. [PMID: 31455302 DOI: 10.1186/s12888-019-2237-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
301 Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H, Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T, Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E, Tomita H, Ohi K, Muraoka H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A, Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga JI, Ichihashi K, Ogasawara K, Yamada H, Inada K, Hashimoto R. Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci 2019;73:642-8. [PMID: 31437336 DOI: 10.1111/pcn.12911] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
302 Bares M, Novak T, Vlcek P, Hejzlar M, Brunovsky M. Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants. Int J Psychophysiol 2019;143:1-8. [PMID: 31195067 DOI: 10.1016/j.ijpsycho.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
303 Benoit JRA, Dursun SM, Greiner R, Cao B, Brown MRG, Lam RW, Greenshaw AJ. Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine : Utiliser l'apprentissage machine pour prédire la rémission chez les patients souffrant de trouble dépressif majeur traités par desvenlafaxine. Can J Psychiatry 2021;:7067437211037141. [PMID: 34379019 DOI: 10.1177/07067437211037141] [Reference Citation Analysis]
304 Maciukiewicz M, Marshe VS, Hauschild AC, Foster JA, Rotzinger S, Kennedy JL, Kennedy SH, Müller DJ, Geraci J. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. J Psychiatr Res 2018;99:62-8. [PMID: 29407288 DOI: 10.1016/j.jpsychires.2017.12.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
305 Courtney DB, Watson P, Chan BW, Bennett K, Krause KR, Offringa M, Butcher NJ, Monga S, Neprily K, Zentner T, Rodak T, Szatmari P. Forks in the road: Definitions of response, remission, recovery, and other dichotomized outcomes in randomized controlled trials for adolescent depression. A scoping review. Depress Anxiety 2021. [PMID: 34312952 DOI: 10.1002/da.23200] [Reference Citation Analysis]
306 Valerio MP, Szmulewicz AG, Martino DJ. A quantitative review on outcome-to-antidepressants in melancholic unipolar depression. Psychiatry Res 2018;265:100-10. [PMID: 29702301 DOI: 10.1016/j.psychres.2018.03.088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
307 MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, Han X, Baillie RA, Arnold M, Skime MK, John-Williams LS, Moseley MA, Thompson JW, Louie G, Riva-Posse P, Craighead WE, McDonald W, Krishnan R, Rush AJ, Frye MA, Dunlop BW, Weinshilboum RM, Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC). Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Transl Psychiatry 2021;11:153. [PMID: 33654056 DOI: 10.1038/s41398-020-01097-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
308 Ayani N, Matsuoka T, Yamano S, Narumoto J. Depression Relapse during Long-Term Remission due to Media-Amplified Fear during the COVID-19 Pandemic. Case Rep Psychiatry 2021;2021:5682611. [PMID: 34659857 DOI: 10.1155/2021/5682611] [Reference Citation Analysis]
309 Papastergiou J, Quilty LC, Li W, Thiruchselvam T, Jain E, Gove P, Mandlsohn L, van den Bemt B, Pojskic N. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clin Transl Sci 2021;14:1359-68. [PMID: 33641259 DOI: 10.1111/cts.12986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Baldaçara L, Rocha GA, Leite VDS, Porto DM, Grudtner RR, Diaz AP, Meleiro A, Correa H, Tung TC, Quevedo J, da Silva AG. Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 1. Risk factors, protective factors, and assessment. Braz J Psychiatry 2020:S1516-44462020005035202. [PMID: 33111773 DOI: 10.1590/1516-4446-2020-0994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
311 Shiwaku H, Fujita M, Takahashi H. Benzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression. J Clin Med 2020;9:E1938. [PMID: 32575832 DOI: 10.3390/jcm9061938] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
312 Morlet E, Costemale-lacoste J, Poulet E, Mcmahon K, Hoertel N, Limosin F, Adès J, Alezrah C, Amado I, Amar G, Andréi O, Arbault D, Archambault G, Aurifeuille G, Barrière S, Béra-potelle C, Blumenstock Y, Bardou H, Bareil-guérin M, Barrau P, Barrouillet C, Baup E, Bazin N, Beaufils B, Ben Ayed J, Benoit M, Benyacoub K, Bichet T, Blanadet F, Blanc O, Blanc-comiti J, Boussiron D, Bouysse A, Brochard A, Brochart O, Bucheron B, Cabot M, Camus V, Chabannes J, Charlot V, Charpeaud T, Clad-mor C, Combes C, Comisu M, Cordier B, Costi F, Courcelles J, Creixell M, Cuche H, Cuervo-lombard C, Dammak A, Da Rin D, Denis J, Denizot H, Deperthuis A, Diers E, Dirami S, Donneau D, Dreano P, Dubertret C, Duprat E, Duthoit D, Fernandez C, Fonfrede P, Freitas N, Gasnier P, Gauillard J, Getten F, Gierski F, Godart F, Gourevitch R, Grassin Delyle A, Gremion J, Gres H, Griner V, Guerin-langlois C, Guggiari C, Guillin O, Hadaoui H, Haffen E, Hanon C, Haouzir S, Hazif-thomas C, Heron A, Hubsch B, Jalenques I, Januel D, Kaladjian A, Karnycheff J, Kebir O, Krebs M, Lajugie C, Leboyer M, Legrand P, Lejoyeux M, Lemaire V, Leroy E, Levy-chavagnat D, Leydier A, Liling C, Llorca P, Loeffel P, Louville P, Lucas Navarro S, Mages N, Mahi M, Maillet O, Manetti A, Martelli C, Martin P, Masson M, Maurs-ferrer I, Mauvieux J, Mazmanian S, Mechin E, Mekaoui L, Meniai M, Metton A, Mihoubi A, Miron M, Mora G, Niro Adès V, Nubukpo P, Omnes C, Papin S, Paris P, Passerieux C, Pellerin J, Perlbarg J, Perron S, Petit A, Petitjean F, Portefaix C, Pringuey D, Radtchenko A, Rahiou H, Raucher-chéné D, Rauzy A, Reinheimer L, Renard M, René M, Rengade C, Reynaud P, Robin D, Rodrigues C, Rollet A, Rondepierre F, Rousselot B, Rubingher S, Saba G, Salvarelli J, Samuelian J, Scemama-ammar C, Schurhoff F, Schuster J, Sechter D, Segalas B, Seguret T, Seigneurie A, Semmak A, Slama F, Taisne S, Taleb M, Terra J, Thefenne D, Tran E, Tourtauchaux R, Vacheron M, Vandel P, Vanhoucke V, Venet E, Verdoux H, Viala A, Vidon G, Vitre M, Vurpas J, Wagermez C, Walter M, Yon L, Zendjidjian X. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study. Journal of Affective Disorders 2019;259:210-7. [DOI: 10.1016/j.jad.2019.08.056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
313 Kim JM, Stewart R, Kang HJ, Kim JW, Lee HJ, Jhon M, Lee JY, Kim SW, Shin IS. Predictors of relapse following a stepwise psychopharmacotherapy regime in patients with depressive disorders. J Affect Disord 2021;293:109-16. [PMID: 34175592 DOI: 10.1016/j.jad.2021.06.015] [Reference Citation Analysis]
314 Bayes A, Parker G. How to choose an antidepressant medication. Acta Psychiatr Scand 2019;139:280-91. [DOI: 10.1111/acps.13001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
315 Salahudeen MS, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. [PMID: 32782779 DOI: 10.1177/2042098620937899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
316 Belzeaux R, Gorgievski V, Fiori LM, Lopez JP, Grenier J, Lin R, Nagy C, Ibrahim EC, Gascon E, Courtet P, Richard-Devantoy S, Berlim M, Chachamovich E, Théroux JF, Dumas S, Giros B, Rotzinger S, Soares CN, Foster JA, Mechawar N, Tall GG, Tzavara ET, Kennedy SH, Turecki G. GPR56/ADGRG1 is associated with response to antidepressant treatment. Nat Commun 2020;11:1635. [PMID: 32242018 DOI: 10.1038/s41467-020-15423-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
317 Elbakary N, Ouanes S, Riaz S, Abdallah O, Mahran I, Al-Khuzaei N, Eltorki Y. Prevalence, median time, and associated factors with the likelihood of initial antidepressant change: a cross-sectional study in Qatar. BMC Psychiatry 2021;21:115. [PMID: 33618690 DOI: 10.1186/s12888-021-03099-0] [Reference Citation Analysis]
318 Belzeaux R, Lin R, Ju C, Chay MA, Fiori LM, Lutz PE, Turecki G. Transcriptomic and epigenomic biomarkers of antidepressant response. J Affect Disord 2018;233:36-44. [PMID: 28918100 DOI: 10.1016/j.jad.2017.08.087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
319 Gabriel FC, de Melo DO, Fráguas R, Leite-Santos NC, Mantovani da Silva RA, Ribeiro E. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One 2020;15:e0231700. [PMID: 32315333 DOI: 10.1371/journal.pone.0231700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
320 MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, Ravindran AV; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Can J Psychiatry 2016;61:588-603. [PMID: 27486149 DOI: 10.1177/0706743716659276] [Cited by in Crossref: 84] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
321 Dos Santos ÉN, Molina ML, Mondin T, Cardoso TA, Silva R, Souza L, Jansen K. Long-term effectiveness of two models of brief psychotherapy for depression: A three-year follow-up randomized clinical trial. Psychiatry Res 2020;286:112804. [PMID: 32001003 DOI: 10.1016/j.psychres.2020.112804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Wang Z, Ma X, Xiao C. Standardized Treatment Strategy for Depressive Disorder. Adv Exp Med Biol 2019;1180:193-9. [PMID: 31784964 DOI: 10.1007/978-981-32-9271-0_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
323 Xiao L, Zhu X, Gillespie A, Feng Y, Zhou J, Chen X, Gao Y, Wang X, Ma X, Gao C, Xie Y, Pan X, Bai Y, Xu X, Wang G, Chen R. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med 2021;51:1166-74. [PMID: 31931894 DOI: 10.1017/S0033291719004069] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Tanner JA, Brown LC, Yu K, Li J, Dechairo BM. Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications. Clinicoecon Outcomes Res 2019;11:779-87. [PMID: 31849503 DOI: 10.2147/CEOR.S224277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
325 Hede V, Favre S, Aubry JM, Richard-Lepouriel H. Bipolar spectrum disorder: What evidence for pharmacological treatment? A systematic review. Psychiatry Res 2019;282:112627. [PMID: 31677696 DOI: 10.1016/j.psychres.2019.112627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
326 Zhu Y, Wu Z, Sie O, Cai Y, Huang J, Liu H, Yao Y, Niu Z, Wu X, Shi Y, Zhang C, Liu T, Rong H, Yang H, Peng D, Fang Y. Causes of drug discontinuation in patients with major depressive disorder in China. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020;96:109755. [DOI: 10.1016/j.pnpbp.2019.109755] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
327 Mora C, Zonca V, Riva MA, Cattaneo A. Blood biomarkers and treatment response in major depression. Expert Review of Molecular Diagnostics 2018;18:513-29. [DOI: 10.1080/14737159.2018.1470927] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
328 Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol 2019;34:110-8. [PMID: 30870236 DOI: 10.1097/YIC.0000000000000256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
329 Zhang J, Liu Y, Xu Y. Soothing liver-qi stagnation method for cancer-related depression: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22797. [PMID: 33120798 DOI: 10.1097/MD.0000000000022797] [Reference Citation Analysis]
330 Bakouni H, Berbiche D, Vasiliadis HM. Off-label use of antipsychotics and associated factors in community living older adults.. Aging Ment Health 2019;23:158-65. [PMID: 29156947 DOI: 10.1080/13607863.2017.1401583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
331 Abou El-Magd RM, Obuobi-Donkor G, Adu MK, Lachowski C, Duddumpudi S, Lawal MA, Sapara AO, Achor M, Kouzehgaran M, Hegde R, Chew C, Mach M, Daubert S, Urichuk L, Snaterse M, Surood S, Li D, Greenshaw A, Agyapong VIO. Repetitive Transcranial Magnetic Stimulation With and Without Internet-Delivered Cognitive-Behavioral Therapy for the Treatment of Resistant Depression: Protocol for Patient-Centered Randomized Controlled Pilot Trial. JMIR Res Protoc 2020;9:e18843. [PMID: 33107835 DOI: 10.2196/18843] [Reference Citation Analysis]
332 Chow TK, Kennedy S, Rizvi SJ. Anhedonia as a Crucial Factor of Depression: Assessment, Neurobiological Underpinnings and Treatment. In: Kim Y, editor. Understanding Depression. Singapore: Springer; 2018. pp. 99-112. [DOI: 10.1007/978-981-10-6577-4_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
333 Bauer M, Severus E, Möller H, Young AH; WFSBP Task Force on Unipolar Depressive Disorders. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. International Journal of Psychiatry in Clinical Practice 2017;21:166-76. [DOI: 10.1080/13651501.2017.1306082] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
334 Ghanean H, Ceniti AK, Kennedy SH. Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management. CNS Drugs 2018;32:65-74. [PMID: 29383573 DOI: 10.1007/s40263-018-0490-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
335 Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol 2018;29:101-11. [PMID: 29272358 DOI: 10.1093/annonc/mdx526] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
336 Liu B, Liu J, Wang M, Zhang Y, Li L. From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder. Front Cell Neurosci 2017;11:305. [PMID: 29033793 DOI: 10.3389/fncel.2017.00305] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
337 van Dun K, Mitoma H, Manto M. Cerebellar Cortex as a Therapeutic Target for Neurostimulation. Cerebellum 2018;17:777-87. [PMID: 30276522 DOI: 10.1007/s12311-018-0976-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
338 Benrimoh D, Tanguay-Sela M, Perlman K, Israel S, Mehltretter J, Armstrong C, Fratila R, Parikh SV, Karp JF, Heller K, Vahia IV, Blumberger DM, Karama S, Vigod SN, Myhr G, Martins R, Rollins C, Popescu C, Lundrigan E, Snook E, Wakid M, Williams J, Soufi G, Perez T, Tunteng JF, Rosenfeld K, Miresco M, Turecki G, Gomez Cardona L, Linnaranta O, Margolese HC. Using a simulation centre to evaluate preliminary acceptability and impact of an artificial intelligence-powered clinical decision support system for depression treatment on the physician-patient interaction. BJPsych Open 2021;7:e22. [PMID: 33403948 DOI: 10.1192/bjo.2020.127] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
339 Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P, Demas ML. Esketamine for treatment resistant depression. Expert Rev Neurother 2019;19:899-911. [PMID: 31282772 DOI: 10.1080/14737175.2019.1640604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
340 Cosci F, Mansueto G, Fava GA. Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. Int J Psychiatry Clin Pract 2020;24:341-8. [PMID: 32716222 DOI: 10.1080/13651501.2020.1779308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
341 Hong RH, Murphy JK, Michalak EE, Chakrabarty T, Wang Z, Parikh SV, Culpepper L, Yatham LN, Lam RW, Chen J. Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. Neuropsychiatr Dis Treat 2021;17:79-90. [PMID: 33469295 DOI: 10.2147/NDT.S283731] [Reference Citation Analysis]
342 Gündüz Ş, Kandeğer A, Selvi Y. Comparison of venlafaxine alone versus venlafaxine plus late partial sleep deprivation therapy combination for major depressive disorder. Chronobiol Int 2021;38:378-86. [PMID: 33317355 DOI: 10.1080/07420528.2020.1842753] [Reference Citation Analysis]
343 Siegel AN, Rodrigues N, Nasri F, Wilkialis L, Lipsitz O, Lee Y, Gill H, Subramaniapillai M, Phan L, Majeed A, Lui LMW, Rashidian H, Ho R, Toma S, Goldstein BI, Mansur RB, McIntyre RS, Rosenblat JD. Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. Prog Neuropsychopharmacol Biol Psychiatry 2021;104:110032. [PMID: 32634540 DOI: 10.1016/j.pnpbp.2020.110032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
344 Lew SY, Teoh SL, Lim SH, Lim LW, Wong KH. Discovering the Potentials of Medicinal Mushrooms in Combating Depression - A Review. Mini Rev Med Chem 2020;20:1518-31. [PMID: 32452327 DOI: 10.2174/1389557520666200526125534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
345 Vinkers CH, Ruhé HG, Penninx BW. Antidepressant Discontinuation: In Need of Scientific Evidence. J Clin Psychopharmacol 2021;41:512-5. [PMID: 34412108 DOI: 10.1097/JCP.0000000000001460] [Reference Citation Analysis]
346 Ulrich S, Ricken R, Buspavanich P, Schlattmann P, Adli M. Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression: A Systematic Review and Comprehensive Meta-analysis. J Clin Psychopharmacol 2020;40:63-74. [PMID: 31834088 DOI: 10.1097/JCP.0000000000001153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
347 Benrimoh D, Fratila R, Israel S, Perlman K, Mirchi N, Desai S, Rosenfeld A, Knappe S, Behrmann J, Rollins C, You RP, Aifred Health Team T. Aifred Health, a Deep Learning Powered Clinical Decision Support System for Mental Health. In: Escalera S, Weimer M, editors. The NIPS '17 Competition: Building Intelligent Systems. Cham: Springer International Publishing; 2018. pp. 251-87. [DOI: 10.1007/978-3-319-94042-7_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
348 Fiedorowicz JG, Merranko JA, Iyengar S, Hower H, Gill MK, Yen S, Goldstein TR, Strober M, Hafeman D, Keller MB, Goldstein BI, Diler RS, Hunt JI, Birmaher BB. Validation of the youth mood recurrences risk calculator in an adult sample with bipolar disorder. J Affect Disord 2021;295:1482-8. [PMID: 34563392 DOI: 10.1016/j.jad.2021.09.037] [Reference Citation Analysis]
349 Serretti A. The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clin Psychopharmacol Neurosci 2018;16:1-6. [PMID: 29397661 DOI: 10.9758/cpn.2018.16.1.1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
350 Belzeaux R, Lin R, Turecki G. Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants. CNS Drugs 2017;31:253-62. [PMID: 28290081 DOI: 10.1007/s40263-017-0418-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
351 Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. Front Psychiatry 2020;11:844. [PMID: 33005153 DOI: 10.3389/fpsyt.2020.00844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
352 Corponi F, Fabbri C, Serretti A. Pharmacogenetics and Depression: A Critical Perspective. Psychiatry Investig 2019;16:645-53. [PMID: 31455064 DOI: 10.30773/pi.2019.06.16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
353 Khater SE, El-Khouly A, Abdel-Bar HM, Al-Mahallawi AM, Ghorab DM. Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection. Int J Pharm 2021;607:121023. [PMID: 34416332 DOI: 10.1016/j.ijpharm.2021.121023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]